Clinical trial
Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma
NCT00200577 · Nantes University Hospital, Other · Completed
Key facts
| NCT number | NCT00200577 |
|---|---|
| Title | Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma |
| Official title | TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision |
| Acronym | TIL |
| Lead sponsor | Nantes University Hospital, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | TIL + IL2 |
| Enrollment | 70 |
| Start date | May 1, 2005 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 1, 2017 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: